Dermata must file a new drug application with the FDA.
Steady: 0 in the last 7 days
Updated oct 15
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dermata must file a new drug application with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Dermata pivoted learnings from prescription ingredients to a new brand, Tome. Tom Hale cofounded the company and remains involved in leadership.Sub-event
Dermata is required to submit a new drug application to the FDA.1 source
- Dermata's product is a topical botulinum toxin treatment.
Keep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA provided guidance for HCW Biologics' IND application.
- New FDA rule threatens the ability to import medicines.
- The FDA identified deficiencies in a drug application submitted by Aquestive Therapeutics, Inc.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Coverage
Newest first; wire copies grouped- ACCESS NewswireDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Ac
- Unknown outlet